ImmuCell Corporation Reports 46% Jump in Q3 Sales to $8.0 Million
ImmuCell Corporation (ICCC) generated preliminary Q3 2026 sales of $8.0 million, representing a 46% increase compared to the same period last year. For the first nine months of 2026, cumulative sales grew 27.8% year over year to reach $25.6 million. Domestic sales in the U.S. expanded 29.2% to $6.9 million during the quarter.
The revenue expansion was supported by growth across key product offerings. Third-quarter sales of Tri-Shield increased 51% compared to the prior year, while Dual-Force sales rose 36% and feed product sales grew 37%. The broad revenue gains reflect strong demand across the company's product portfolio.
Management plans to discontinue early sales pre-announcements moving forward. Investors will gain further insight into overall profitability, gross margins, and net earnings when full Q3 financial results are reported on November 13, 2026.
Key points
- ImmuCell reported preliminary Q3 2026 sales of $8.0 million, up 46% year over year.
- Nine-month cumulative revenue rose 27.8% to $25.6 million.
- Domestic U.S. sales grew 29.2% to $6.9 million during the third quarter.
- Product growth was led by Tri-Shield, which surged 51% compared to the previous year.
- Management will end early sales updates and report full financial results on November 13, 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What were ImmuCell's Q3 2026 sales?
ImmuCell Corporation reported preliminary Q3 2026 sales of $8.0 million, up 46% year over year.
When will ImmuCell discuss its full Q3 financial results?
Management will review complete third-quarter financial results, including margins and earnings, on November 13, 2026.